key is0 value isNurix Therapeutics Announces Pricing of $209 Million Initial Public Offering
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-pricing-209-million-initial-public
date2020-07-23T18:25:00
dateJuly 23, 2020
key is1 value isNurix Therapeutics Announces Addition of Dr. Jason Kantor to its Management Team
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-addition-dr-jason-kantor-its
date2020-07-13T17:00:00
dateJuly 13, 2020
key is2 value isNurix Therapeutics Announces Formation of DeCART Therapeutics to Advance New CAR T Therapies Using Targeted Protein Modulation
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-formation-decart-therapeutics
date2020-06-25T08:00:00
dateJune 25, 2020
key is3 value isNurix Therapeutics Closes $120 Million Financing to Advance Targeted Protein Modulation Drug Pipeline
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-closes-120-million-financing-advance-targeted
date2020-03-12T08:00:00
dateMarch 12, 2020
key is4 value isNurix Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-present-cowen-co-40th-annual-health-care
date2020-02-27T08:00:00
dateFebruary 27, 2020
key is5 value isNurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-and-sanofi-establish-strategic-collaboration
date2020-01-09T08:00:00
dateJanuary 09, 2020
key is6 value isNurix Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-present-38th-annual-jp-morgan-healthcare
date2020-01-08T08:00:00
dateJanuary 08, 2020
key is7 value isNurix Therapeutics Announces Scientific Presentations on its BTK Program at the 61st American Society of Hematology Annual Meeting
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-scientific-presentations-its-btk
date2019-11-18T08:00:00
dateNovember 18, 2019
key is8 value isNurix Therapeutics Announces Key Management Additions
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-key-management-additions
date2019-11-14T08:00:00
dateNovember 14, 2019
key is9 value isNurix Therapeutics Announces Upcoming Investor Conference Schedule
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-upcoming-investor-conference
date2019-11-12T08:00:00
dateNovember 12, 2019
key is10 value isNurix Therapeutics Announces Upcoming Scientific Presentation for its CBL-B Program at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-upcoming-scientific-presentation
date2019-10-22T08:00:00
dateOctober 22, 2019
key is11 value isNurix Therapeutics to Present at the Targeted Protein Degradation Summit 2019
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-present-targeted-protein-degradation-summit
date2019-10-15T08:00:00
dateOctober 15, 2019
key is12 value isNurix Therapeutics Announces Key Additions to its Board of Directors
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-key-additions-its-board-directors
date2019-10-08T08:00:00
dateOctober 08, 2019
key is13 value isGilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases
value ishttp://ir.nurixtx.com/news-releases/news-release-details/gilead-and-nurix-establish-strategic-collaboration-develop-novel
date2019-06-19T08:00:00
dateJune 19, 2019
key is14 value isNurix Therapeutics to Present at the Needham & Company 18th Annual Healthcare Conference
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-present-needham-company-18th-annual
date2019-04-04T08:00:00
dateApril 04, 2019
key is15 value isNurix Therapeutics to Present at 2019 American Association for Cancer Research (AACR) Annual Meeting
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-present-2019-american-association-cancer
date2019-03-19T08:00:00
dateMarch 19, 2019
key is16 value isNurix Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-present-30th-annual-piper-jaffray-healthcare
date2018-11-21T08:00:00
dateNovember 21, 2018
key is17 value isNurix Therapeutics to Present at the Stifel Healthcare Conference
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-present-stifel-healthcare-conference
date2018-11-07T08:00:00
dateNovember 07, 2018
key is18 value isNurix Therapeutics to Present at the Targeted Protein Degradation Summit 2018
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-present-targeted-protein-degradation-summit-0
date2018-10-17T08:00:00
dateOctober 17, 2018
key is19 value isNurix Therapeutics to Present at the 2018 BIO Investor Forum
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-present-2018-bio-investor-forum
date2018-10-10T08:00:00
dateOctober 10, 2018
key is20 value isNurix Appoints Nancy Pryer, Ph.D., Chief Development Officer
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-appoints-nancy-pryer-phd-chief-development-officer
date2018-05-08T08:00:00
dateMay 08, 2018
key is21 value isNurix Appoints Dr. Robert Tjian to its Board of Directors
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-appoints-dr-robert-tjian-its-board-directors
date2016-12-06T08:00:00
dateDecember 06, 2016
key is22 value isNurix Strengthens Executive Leadership Team
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-strengthens-executive-leadership-team
date2016-05-03T08:00:00
dateMay 03, 2016
key is23 value isNurix Announces New Appointments to its Board of Directors
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-announces-new-appointments-its-board-directors
date2016-05-03T08:00:00
dateMay 03, 2016
key is24 value isCelgene and Nurix Announce Collaboration Targeting Protein Homeostasis for Next-Generation Therapies in Oncology, Inflammation and Immunology
value ishttp://ir.nurixtx.com/news-releases/news-release-details/celgene-and-nurix-announce-collaboration-targeting-protein
date2015-09-16T08:00:00
dateSeptember 16, 2015
key is25 value isNurix Launches Collaboration with Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute to Expand its Drug Discovery Program
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-launches-collaboration-mount-sinai-hospitals-lunenfeld
date2014-12-02T08:00:00
dateDecember 02, 2014
key is26 value isNurix, Inc. Names Arthur T. Sands, M.D., Ph.D., Chief Executive Officer
value ishttp://ir.nurixtx.com/news-releases/news-release-details/nurix-inc-names-arthur-t-sands-md-phd-chief-executive-officer
date2014-09-18T08:00:00
dateSeptember 18, 2014
key is27 value isThird Rock Ventures and The Column Group Launch Nurix with $25.1 Million Financing to Target Key Regulatory Pathway
value ishttp://ir.nurixtx.com/news-releases/news-release-details/third-rock-ventures-and-column-group-launch-nurix-251-million
date2014-05-22T08:00:00
dateMay 22, 2014

News